Evaluating the efficacy of Etoricoxib in reducing post-operative pain associated with minor oral surgery. A randomized clinical trial
DOI:
https://doi.org/10.4322/bds.2023.e3854Abstract
Etoricoxib, a new cyclooxygenase-2-selective inhibitor has demonstrated a rapid onset analgesic effect for relieving acute pain especially when prescribed as a pre-emptive medication. On these bases, this study may provide useful information and guidance for clinicians working in the field of oral surgery, as regards handling odontogenic pain and postoperative pain precisely with cyclooxygenase-2 inhibitors. Objective: the study aimed to measure the quantifiable efficacy of Etoricoxib in reducing post-extraction pain in subjects undergoing minor oral surgical intervention as compared to Naproxen (a traditional NSAID) which is commonly used to control postoperative pain. Material and Methods: a 120 mg film-coated tablet of Etoricoxib was given to each of the twenty patients representing the study group, and a 500 mg tablet of Naproxen was given to each of the other twenty subjects representing the positive control group. According to manufacturer instructions, the tablets were given to the subjects 30 minutes pre-operatively (before dental extraction). Post-operative pain was assessed for each subject using eleven points from zero to ten, visual analog scale. Results: showed no statistically significant difference between Etoricoxib and Naproxen in decreasing post-extraction odontogenic pain, suggesting that Etoricoxib is as efficient as Naproxen in the control of discomfort with dental origin taking into consideration the patient’s status when prescribing the medication. Conclusion: this study suggests that Etoricoxib can be handled as a pre-emptive medication to reduce post-operative pain for subjects seeking traditional or surgical extraction of any of their teeth.
KEYWORDS
Etoricoxib; Pain; Oral surgery; Clinical Trial
Published
Issue
Section
License
COPYRIGHT TRANSFER AND RESPONSIBILITY STATEMENT
(PDF)
For all articles published in the BDS journal, copyright is retained by the authors. Articles are licensed under an open-access Creative Commons CC BY 4.0 license, meaning that anyone may download and read the paper for free. In addition, the article may be reused and quoted, provided that the original published version is cited. These conditions allow for maximum use and exposure of the work while ensuring that the authors receive proper credit. All metadata associated with published articles is released under the Creative Commons CC0 Universal Public Domain Dedication.
Before the submission, authors must obtain permission to reproduce any published material (figures, schemes, tables, or any extract of a text) that does not fall into the public domain or for which they do not hold the copyright. Permission should be requested by the authors from the copyright holder (usually the Publisher, please refer to the imprint of the individual publications to identify the copyright holder).
The authors hereby attest that the study is original and does not present manipulated data, fraud, or plagiarism. All names listed made a significant scientific contribution to the study, are aware of the presented data, and agree with the final version of the manuscript. They assume complete responsibility for the ethical aspects of the study.
This text must be printed and signed by all authors. The scanned version should be submitted as supplemental file during the submission process.
